베리카 파머슈티컬스(VRCA)는 NAS에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $4.45 (-4.30%), 시가총액 $103.42M, 52주 범위 $0.49 ~ $9.10.
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications.
베리카 파머슈티컬스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 XTS에서 실시간으로 확인할 수 있습니다.
베리카 파머슈티컬스의 현재 주가는 $4.45 (-4.30%)입니다. XTS에서 실시간 시세와 차트를 확인할 수 있습니다.
베리카 파머슈티컬스의 시가총액은 약 $103.42M입니다.
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States.